Herantis Pharma to Participate in Three Upcoming Virtual Investor Conferences

Herantis Pharma Plc
Company release 04 Mar 2021 at 8:00 am

Herantis Pharma Plc

Company Release 4 March 2021 at 8:00 a.m. EET

Press Release

Herantis Pharma Plc (“Herantis”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today announced that Craig Cook, Chief Executive Officer, will be participating at the upcoming virtual investor conferences, where he will be presenting and holding 1×1 meetings.

Event: H.C. Wainwright Global Life Sciences Conference

Format: Presentation & 1×1’s

Dates: March 9 – 10, 2021

Webcasting link: https://journey.ct.events/view/e89fea7e-ce72-4238-a8b1-94459dd7fb9e

The session time is on-demand and is for March 9 starting at 7:00 am (EST), archived for 90 days.

Event: Carnegie Nordic Healthcare Virtual Seminar 2021

Format: Presentation & 1×1’s

Dates: March 9 – 12, 2021

Presentation: March 12th, 2021 at 09:00 a.m. CET/ 10:00 a.m. EET

Event: BIO-Europe Spring Digital 2021

Format: Presentation & 1×1’s

Dates: March 22 – 25, 2021

Presentation: On-demand after March 22, 2021 when registered for BIO-Europe Spring Digital 2021

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases and break the boundaries of standard therapeutic approaches. Leveraging deep scientific brilliance in protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis is advancing a rich pipeline of regenerative biological and gene therapies for high impact diseases.  These include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, and ii. Lymfactin® VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases.  Herantis is pursuing disease modifying treatments that slow, stop, or even reverse the course of diseases, and bring much needed innovation to these underserved diseases.  The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit https://www.herantis.com

Attachment